DK2879691T3 - Fremgangsmåder og sammensætninger til inaktivering af kappebærende vira - Google Patents
Fremgangsmåder og sammensætninger til inaktivering af kappebærende vira Download PDFInfo
- Publication number
- DK2879691T3 DK2879691T3 DK13750235.7T DK13750235T DK2879691T3 DK 2879691 T3 DK2879691 T3 DK 2879691T3 DK 13750235 T DK13750235 T DK 13750235T DK 2879691 T3 DK2879691 T3 DK 2879691T3
- Authority
- DK
- Denmark
- Prior art keywords
- disabling
- creative
- wear
- compositions
- methods
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- C12N2710/16761—Methods of inactivation or attenuation
- C12N2710/16763—Methods of inactivation or attenuation by chemical treatment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
- C12N2740/13061—Methods of inactivation or attenuation
- C12N2740/13063—Methods of inactivation or attenuation by chemical treatment
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Dermatology (AREA)
- Toxicology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261680039P | 2012-08-06 | 2012-08-06 | |
| PCT/US2013/053781 WO2014025771A2 (en) | 2012-08-06 | 2013-08-06 | Methods and compositions for inactivating enveloped viruses |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2879691T3 true DK2879691T3 (da) | 2019-06-11 |
Family
ID=48986268
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK13750235.7T DK2879691T3 (da) | 2012-08-06 | 2013-08-06 | Fremgangsmåder og sammensætninger til inaktivering af kappebærende vira |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US10188732B2 (https=) |
| EP (2) | EP2879691B1 (https=) |
| JP (2) | JP6465800B2 (https=) |
| DK (1) | DK2879691T3 (https=) |
| WO (1) | WO2014025771A2 (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10188732B2 (en) | 2012-08-06 | 2019-01-29 | Biogen Ma Inc. | Methods and compositions for inactivating enveloped viruses |
| CA2961510A1 (en) | 2014-09-17 | 2016-03-24 | Helixbind, Inc. | Methods and devices for detecting and identifying microorganisms |
| AR102198A1 (es) | 2014-10-09 | 2017-02-08 | Regeneron Pharma | Proceso para reducir partículas subvisibles en una formulación farmacéutica |
| EP3420341B1 (en) * | 2016-02-24 | 2020-11-18 | Bio-Rad Laboratories, Inc. | Methods and compositions for fluorescence detection |
| US11020686B2 (en) | 2016-08-16 | 2021-06-01 | Regeneron Pharmaceuticals, Inc. | Methods for quantitating individual antibodies from a mixture |
| JP7102401B2 (ja) | 2016-10-25 | 2022-07-19 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | クロマトグラフィーデータ解析のための方法およびシステム |
| EP3446710A1 (en) * | 2017-08-25 | 2019-02-27 | Glenmark Pharmaceuticals S.A. | Methods of inactivating viral contaminants |
| US11564392B2 (en) | 2017-09-18 | 2023-01-31 | Bayer Healthcare Llc | Methods of inactivation of viruses using n-methlyglucamide and its derivatives |
| CA3073935A1 (en) | 2017-09-19 | 2019-03-28 | Regeneron Pharmaceuticals, Inc. | Methods of reducing particle formation and compositions formed thereby |
| ES2991988T3 (es) | 2017-10-30 | 2024-12-05 | Takeda Pharmaceuticals Co | Detergentes compatibles con el medio ambiente para la inactivación de virus con envoltura lipídica |
| TWI853823B (zh) | 2018-07-02 | 2024-09-01 | 美商里珍納龍藥品有限公司 | 自混合物製備多肽之系統及方法 |
| WO2020102505A1 (en) | 2018-11-15 | 2020-05-22 | Bayer Healthcare Llc | Viral inactivation methods for continuous manufacturing of antibodies |
| EA202192422A1 (ru) | 2019-03-05 | 2021-12-09 | Ридженерон Фармасьютикалз, Инк. | Человеческий сывороточный альбумин в составах |
| SG11202109801YA (en) * | 2019-03-19 | 2021-10-28 | Amgen Inc | Alternate detergents for viral inactivation |
| CN110424030B (zh) * | 2019-08-30 | 2020-06-30 | 广州三孚新材料科技股份有限公司 | 无氰碱性电镀铜液及其制备和在挠性印刷线路板中的应用 |
| EP4150101A2 (en) * | 2020-05-14 | 2023-03-22 | Merck Patent GmbH | Methods and compositions for purifying adeno associated virus particles or adenoviruses |
| US11643641B2 (en) | 2021-03-04 | 2023-05-09 | Malireddy S. Reddy | Prevention of viral transmission by naked genetic material |
| CN117836010A (zh) | 2021-06-21 | 2024-04-05 | 优尼科生物制药有限公司 | 改进的裂解程序 |
| WO2024115344A1 (en) | 2022-11-29 | 2024-06-06 | Merck Patent Gmbh | Method for inactivating enveloped viruses |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE242716C (https=) | ||||
| DD242716A3 (de) | 1981-08-28 | 1987-02-11 | Adw Der Ddr Inst F Chem Techno | Verfahren zur herstellung von gereinigten antigenen bzw. biopraeparaten |
| DE3704550A1 (de) * | 1987-02-13 | 1988-08-25 | Behringwerke Ag | Verfahren zur inaktivierung huellhaltiger viren in mittels einer zelle in vitro hergestellten protein-praeparationen |
| GB8927546D0 (en) | 1989-12-06 | 1990-02-07 | Ciba Geigy | Process for the production of biologically active tgf-beta |
| US5314917A (en) | 1991-03-22 | 1994-05-24 | E. B. Michaels Research Associates, Inc. | Method for inactivating enveloped viruses and sperm |
| FR2805163A1 (fr) | 2000-02-21 | 2001-08-24 | Pf Medicament | Utilisation d'un detergent de type zwittergent pour la preparation d'une composition pharmaceutique destinee a etre administree par voie nasale |
| US6635679B2 (en) * | 2001-05-14 | 2003-10-21 | Akzo Nobel N.V. | Methods and compositions for inactivating viruses |
| CN1901935A (zh) | 2003-12-30 | 2007-01-24 | 惠氏公司 | 具有改进耐受性的免疫原组合物中的疏水性蛋白调配物 |
| NZ568211A (en) * | 2005-11-04 | 2011-11-25 | Novartis Vaccines & Diagnostic | Influenza vaccines including combinations of particulate adjuvants and immunopotentiators |
| EP1970440A1 (en) | 2007-03-06 | 2008-09-17 | Qiagen GmbH | Polymerase stabilization by ionic detergents |
| CN103370072B (zh) * | 2010-12-15 | 2016-02-03 | 巴克斯特国际公司 | 使用改进的溶剂-清洁剂方法进行病毒灭活 |
| GB201216121D0 (en) * | 2012-09-10 | 2012-10-24 | Novartis Ag | Sample quantification by disc centrifugation |
| US10188732B2 (en) | 2012-08-06 | 2019-01-29 | Biogen Ma Inc. | Methods and compositions for inactivating enveloped viruses |
-
2013
- 2013-08-06 US US14/419,968 patent/US10188732B2/en active Active
- 2013-08-06 EP EP13750235.7A patent/EP2879691B1/en active Active
- 2013-08-06 WO PCT/US2013/053781 patent/WO2014025771A2/en not_active Ceased
- 2013-08-06 JP JP2015526635A patent/JP6465800B2/ja active Active
- 2013-08-06 DK DK13750235.7T patent/DK2879691T3/da active
- 2013-08-06 EP EP18200752.6A patent/EP3456352A1/en active Pending
-
2018
- 2018-10-09 JP JP2018190622A patent/JP6833788B2/ja active Active
- 2018-12-06 US US16/211,302 patent/US10702603B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP6833788B2 (ja) | 2021-02-24 |
| US10702603B2 (en) | 2020-07-07 |
| JP6465800B2 (ja) | 2019-02-06 |
| EP3456352A1 (en) | 2019-03-20 |
| US10188732B2 (en) | 2019-01-29 |
| WO2014025771A2 (en) | 2014-02-13 |
| US20190175738A1 (en) | 2019-06-13 |
| EP2879691B1 (en) | 2019-03-27 |
| JP2019037234A (ja) | 2019-03-14 |
| EP2879691A2 (en) | 2015-06-10 |
| JP2015525572A (ja) | 2015-09-07 |
| WO2014025771A3 (en) | 2014-04-17 |
| US20150306223A1 (en) | 2015-10-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2879691T3 (da) | Fremgangsmåder og sammensætninger til inaktivering af kappebærende vira | |
| DK2890780T3 (da) | Fremgangsmåder og sammensætninger til behandling af en genetisk tilstand | |
| DK3875104T3 (da) | Sammensætninger til behandling af ineffektiv erytropoiese | |
| DK2773635T3 (da) | Forbindelser og sammensætninger til modulering af EGFR-aktivitet | |
| DK3363901T3 (da) | Sammensætninger og fremgangsmåder til præcis identificering af mutationer | |
| DK2812452T3 (da) | Fremgangsmåder og sammensætninger til screening og behandling af udviklingsforstyrrelser | |
| DK2914741T3 (da) | Hidtil ukendte sammensætninger og fremgangsmåder til forbedring af PCR-specificitet | |
| DK2906696T3 (da) | Fremgangsmåder til modulering af c9orf72-ekspression | |
| DK2838917T3 (da) | Fremgangsmåder og midler til frembringelse af heterodimere ig-lignende molekyler | |
| DK2911506T3 (da) | Driftreducerende sammensætninger | |
| DK2665486T3 (da) | Sammensætninger til modulering af gamma-c-cytokin-aktivitet | |
| BR112013022112A2 (pt) | composição | |
| DK3241547T3 (da) | Lyofiliseret præparat af botulinumtoksin | |
| DK2855500T3 (da) | Fremgangsmåder og sammensætninger til modulering af apolipoprotein (A)-ekspression | |
| DK2766483T3 (da) | Fremgangsmåder og sammensætninger til screening for og behandling af udviklingsforstyrrelser | |
| DK2686017T3 (da) | Oftalmisk sammensætning | |
| BR112014004395A2 (pt) | composição | |
| BR112014032798A2 (pt) | composição | |
| DK2830654T3 (da) | Metoder og sammensætninger til behandling af inflammation | |
| DK2922955T3 (da) | Sammensætninger og fremgangsmåder til modulering af FGFR3-ekspression | |
| EP2842163A4 (en) | NONLINEAR MEMRISTORS | |
| BR112013033808A2 (pt) | composição | |
| EP2730619A4 (en) | COMPOSITION | |
| EP2529947A4 (en) | BINDER | |
| PT2739276T (pt) | Composição antisséptica |